دورية أكاديمية
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate : an analysis of the NETTER-1 study
| العنوان: | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate : an analysis of the NETTER-1 study |
|---|---|
| المؤلفون: | Strosberg, Jonathan, Kunz, Pamela L., Hendifar, Andrew, Yao, James, Bushnell, David, Kulke, Matthew H., Baum, Richard P., Caplin, Martyn, Ruszniewski, Philippe, Delpassand, Ebrahim, Hobday, Timothy, Verslype, Chris, Benson, Al, Srirajaskanthan, Rajaventhan, Pavel, Marianne, Mora, Jaume, Berlin, Jordan, Grande, Enrique, Reed, Nicholas, Seregni, Ettore, Paganelli, Giovanni, Severi, Stefano, Morse, Michael, Metz, David C., Ansquer, Catherine, Courbon, Frederic, Al-Nahhas, Adil, Baudin, Eric, Giammarile, Francesco, Taieb, David, Mittra, Erik, Wolin, Edward, O'Dorisio, Thomas M., Lebtahi, Rachida, Deroose, Christophe M., Grana, Chiara M., Bodei, Lisa, Öberg, Kjell, Polack, Berna Degirmenci, He, Beilei, Mariani, Maurizio F., Gericke, Germo, Santoro, Paola, Erion, Jack L., Ravasi, Laura, Krenning, Eric |
| بيانات النشر: | Uppsala universitet, Endokrin tumörbiologi H Lee Moffitt Canc Ctr & Res Inst, Neuroendocrine Tumor Div, Gastrointestinal Dept, Tampa, FL 33612 USA. Stanford Univ, Med Ctr, Dept Med Med Oncol, Stanford, CA 94305 USA. Cedars Sinai Med Ctr, Dept Internal Med Hematol Oncol, Los Angeles, CA 90048 USA. Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA. Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Zent Klin Bad Berka, Dept Nucl Med, Bad Berka, Germany. Royal Free Hosp, Dept Gastroenterol & Tumour Neuroendocrinol, London, England. Hop Beaujon, Div Gastroenterol & Pancreatol, Clichy, France. Excel Diagnost Imaging Clin, Dept Clin Nucl Med, Houston, TX USA. Mayo Clin, Coll Med, Dept Oncol, Rochester, MN USA. Univ Hosp, Dept Hepatol, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium. Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL USA. Kings Coll Hosp NHS Fdn Trust, Dept Gastroenterol & Gen Internal Med, London, England. Charite Univ Med Berlin, Div Gastroenterol & Hepatol, Berlin, Germany. Hosp Univ Bellvitge, Dept Nucl Med, Barcelona, Spain. Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. MD Anderson Canc Ctr, Dept Med Oncol, Madrid, Spain. Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland. Ist Nazl Tumori, Fdn Ist Ric & Cura Carattere Sci, Dept Nucl Med Therapy & Endocrinol, Milan, Italy. IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Dept Med Oncol, Meldola, Italy. Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. Hosp Univ Penn, GI Div, 3400 Spruce St, Philadelphia, PA 19104 USA. Univ Hosp, Hotel Dieu, Dept Nucl Med, Nantes, France. Oncol Univ, Inst Claudius Regaud, Med Imaging, Toulouse, France. Imperial Coll London, Div Imaging & Intervent Radiol, London, England. Inst Gustave Roussy, Dept Endocrine Oncol & Nucl Med, Villejuif, France. IAEA, Dept Nucl Sci & Applicat, Vienna, Austria. Hop La Timone, Dept Nucl Med, Marseille, France. Oregon Hlth & Sci Univ, Dept Nucl Med, Portland, OR 97201 USA. Icahn Sch Med Mt Sinai, Dept Med Hematol & Med Oncol, New York, NY 10029 USA. Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA. Royal Free Hosp, Dept Nucl Med, London, England. Univ Hosp, Dept Nucl Med, Leuven, Belgium.;Katholieke Univ Leuven, Leuven, Belgium. Ist Europeo Oncol, Div Nucl Med, Milan, Italy. Mem Sloan Kettering Canc Ctr, Dept Nucl Med, 1275 York Ave, New York, NY 10021 USA. Adv Accelerator Applicat, Dept Med Informat, Geneva, Switzerland. Adv Accelerator Applicat, Geneva, Switzerland. Adv Accelerator Applicat, Res & Dev, Geneva, Switzerland. Adv Accelerator Applicat, Dept Clin Dev, Geneva, Switzerland. Erasmus Univ, Med Ctr, Cyclotron Rotterdam BV, Dept Nucl Med, Rotterdam, Netherlands. SPRINGER |
| سنة النشر: | 2020 |
| المجموعة: | Uppsala University: Publications (DiVA) |
| مصطلحات موضوعية: | Lu-177-Dotatate, Liver tumour burden, NETTER-1, Neuroendocrine tumour, Octreotide, Cancer and Oncology, Cancer och onkologi, Radiology, Nuclear Medicine and Medical Imaging, Radiologi och bildbehandling |
| الوصف: | Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate. Methods In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results Significantly prolonged median PFS occurred with Lu-177-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the Lu-177-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions Lu-177-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. : NCT01578239, EudraCT: 2011-005049-11 |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | European Journal of Nuclear Medicine and Molecular Imaging, 1619-7070, 2020, 47:10, s. 2372-2382; http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423870Test; PMID 32123969; ISI:000517706000004 |
| DOI: | 10.1007/s00259-020-04709-x |
| الإتاحة: | https://doi.org/10.1007/s00259-020-04709-xTest http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423870Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F2481264 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00259-020-04709-x |
|---|